Zhang Huayi, Guo Gang, Jianzhong Cao, Zheng Yaqin
Department of Breast Surgery, Shanxi Provincial Tumor Hospital and Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan, Shanxi, China (mainland).
Department of Breast Surgery, Affiliated Hospital of Inner Mongolia Medical University, Huhhot, Inner Mongolia, China (mainland).
Med Sci Monit. 2016 Feb 22;22:587-97. doi: 10.12659/msm.896747.
BACKGROUND The aim of this study was to explore the prevalence of type I allergic diseases in patients with breast cancer by carrying out a questionnaire survey and IgE detection in a healthy population and in patients with breast cancer. MATERIAL AND METHODS There were 309 patients enrolled and they were further divided into the type I allergic disease group, the newly diagnosed breast cancer with type I allergic disease group, the re-visit breast cancer with type I allergic disease group, and the re-visit breast cancer without type I allergic disease group, as well as a healthy control group. Serum total IgE level was detected by immunoassay. RESULTS The IgE value in the healthy population with type I allergic diseases (89.3±51.4 IU/ml) was significantly higher than in those without type I allergic diseases (45.6±65.1 IU/ml). There was no significant difference between IgE values in the re-visit breast cancer patients with type I allergic disease (25.1±65.1 IU/ml) and those without type I allergic disease (23.0±45.9 IU/ml). The area under the ROC curve was 0.618±0.04, sensitivity was 78%, specificity was 47.1%, Youden index was 0.251, and IgE threshold was 32.6 IU/ml. CONCLUSIONS The patients with newly diagnosed breast cancer were susceptible to type I allergic disease at about the same levels as in the healthy population. There was no correlation between breast cancer and type I allergic disease.
背景 本研究旨在通过对健康人群和乳腺癌患者进行问卷调查及IgE检测,探讨乳腺癌患者中I型过敏性疾病的患病率。
材料与方法 共纳入309例患者,进一步分为I型过敏性疾病组、新诊断的伴有I型过敏性疾病的乳腺癌组、复诊的伴有I型过敏性疾病的乳腺癌组、复诊的不伴有I型过敏性疾病的乳腺癌组以及健康对照组。采用免疫分析法检测血清总IgE水平。
结果 I型过敏性疾病的健康人群的IgE值(89.3±51.4 IU/ml)显著高于无I型过敏性疾病的人群(45.6±65.1 IU/ml)。伴有I型过敏性疾病的复诊乳腺癌患者的IgE值(25.1±65.1 IU/ml)与不伴有I型过敏性疾病的患者(23.0±45.9 IU/ml)之间无显著差异。ROC曲线下面积为0.618±0.04,灵敏度为78%,特异度为47.1%,约登指数为0.251,IgE阈值为32.6 IU/ml。
结论 新诊断的乳腺癌患者患I型过敏性疾病的易感性与健康人群大致相同。乳腺癌与I型过敏性疾病之间无相关性。